Stoneridge Investment Partners LLC cut its position in shares of Smith & Nephew PLC (NYSE:SNN) by 61.9% during the second quarter, Holdings Channel reports. The institutional investor owned 75,606 shares of the company’s stock after selling 122,733 shares during the period. Stoneridge Investment Partners LLC’s holdings in Smith & Nephew PLC were worth $2,595,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Renaissance Technologies LLC boosted its stake in Smith & Nephew PLC by 267.7% in the first quarter. Renaissance Technologies LLC now owns 1,111,500 shares of the company’s stock worth $37,035,000 after buying an additional 809,200 shares in the last quarter. Thomas White International Ltd. boosted its stake in Smith & Nephew PLC by 3.9% in the first quarter. Thomas White International Ltd. now owns 286,510 shares of the company’s stock worth $9,547,000 after buying an additional 10,656 shares in the last quarter. Ferguson Wellman Capital Management Inc. boosted its stake in Smith & Nephew PLC by 0.6% in the second quarter. Ferguson Wellman Capital Management Inc. now owns 240,202 shares of the company’s stock worth $8,244,000 after buying an additional 1,369 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Smith & Nephew PLC by 21.7% in the first quarter. Goldman Sachs Group Inc. now owns 149,657 shares of the company’s stock worth $4,986,000 after buying an additional 26,708 shares in the last quarter. Finally, Envestnet Asset Management Inc. boosted its stake in Smith & Nephew PLC by 6.7% in the first quarter. Envestnet Asset Management Inc. now owns 120,863 shares of the company’s stock worth $4,027,000 after buying an additional 7,615 shares in the last quarter. Institutional investors own 5.82% of the company’s stock.

Shares of Smith & Nephew PLC (NYSE:SNN) traded up 0.03% during midday trading on Wednesday, reaching $32.83. The company’s stock had a trading volume of 399,800 shares. Smith & Nephew PLC has a 1-year low of $30.23 and a 1-year high of $36.11. The stock has a 50 day moving average of $33.17 and a 200-day moving average of $33.58. The company has a market capitalization of $14.68 billion, a P/E ratio of 41.35 and a beta of 0.77.

The company also recently declared a dividend, which will be paid on Tuesday, October 25th. Shareholders of record on Friday, October 7th will be paid a $0.236 dividend. The ex-dividend date of this dividend is Wednesday, October 5th.

A number of analysts have recently commented on SNN shares. Zacks Investment Research cut Smith & Nephew PLC from a “hold” rating to a “sell” rating in a research report on Wednesday, July 6th. Barclays PLC cut Smith & Nephew PLC from an “overweight” rating to an “equal weight” rating in a research report on Wednesday, August 10th. Finally, Beaufort Securities reiterated a “hold” rating on shares of Smith & Nephew PLC in a research report on Wednesday, August 10th. One analyst has rated the stock with a sell rating, ten have issued a hold rating and three have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $37.00.

Smith & Nephew PLC Company Profile

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. The Company offers various product franchises, which include Knee implants, Hip implants, Sports Medicine Joint Repair, Arthroscopy Enabling Technologies, Trauma and Extremities, Other Surgical Businesses, Advanced Wound Care, Advanced Wound Devices and Advanced Wound Bioactives.

5 Day Chart for NYSE:SNN

Want to see what other hedge funds are holding SNN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Smith & Nephew PLC (NYSE:SNN).

Receive News & Ratings for Smith & Nephew PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.